PIGW and coccidioidomycosis: Recent positive data with the clinical Gwt1 inhibitors of the APX001 class in models of pulmonary aspergillosis, coccidioidomycosis, and against Candida auris validate the GPI pathway as a valuable druggable biological intervention point to tackle fungal diseases15,38,39.